Noliterax (Indapamide, Perindopril Arginine)

Noliterax is indicated for the management of hypertension, a condition characterised by elevated arterial pressure. It works within the renin‑angiotensin‑aldosterone system and renal sodium handling pathways.

• Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary high blood pressure.
• Secondary hypertension: assists in blood‑pressure control when hypertension is caused by an identifiable underlying condition.
• Cardiovascular risk reduction: contributes to overall risk management in patients with hypertension and additional cardiovascular risk factors.

• Perindopril arginine inhibits angiotensin‑converting enzyme, decreasing formation of angiotensin II and resulting in vasodilation and reduced aldosterone‑mediated sodium retention. Indapamide blocks Na+/Cl‑ reabsorption in the distal renal tubules, promoting diuresis and lowering plasma volume. The combined actions produce additive blood‑pressure reduction through vascular relaxation and decreased fluid overload.

Noliterax may cause a range of adverse reactions, from mild to serious. Awareness of these effects helps clinicians monitor patients appropriately.

Common Side Effects

• Dizziness or light‑headedness, especially after the first dose.
• Persistent dry cough.
• Increased urinary frequency or volume.
• Mild headache.
• Electrolyte disturbances such as low potassium.
• Fatigue or general weakness.

Serious or Rare Side Effects

• Angioedema involving face, lips, tongue or airway.
• Severe hypotension leading to syncope.
• Acute kidney injury or marked rise in serum creatinine.
• Hyperkalemia with potentially life‑threatening cardiac effects.
• Severe allergic reactions (e.g., Stevens‑Johnson syndrome).

Before initiating Noliterax, clinicians should evaluate patient history and monitor relevant parameters.

• Renal function: assess baseline creatinine and eGFR, then monitor periodically.
• Electrolytes: check serum potassium and sodium levels, especially in patients on other diuretics.
• History of angioedema: avoid use in individuals with prior ACE‑inhibitor‑related swelling.
• Pregnancy: use only if the potential benefit justifies the risk, as safety data are limited.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Noliterax can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Aliskiren in patients with diabetes or renal impairment: risk of severe hypotension and renal dysfunction.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• Lithium: increased lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and impair renal function.
• Other antihypertensives (beta‑blockers, calcium channel blockers): may enhance blood‑pressure lowering, requiring dose adjustments.
• Diuretics other than indapamide: additive diuretic effect may cause volume depletion.